1. Pink Sheet
  2. >>Geography
  3. >>Europe

UK HTA Body To Conduct More Appraisals, And Faster, Through Proportionate Approach

 
• By Leela Barham

Faced with the rise in its workload, the UK’s health technology assessment body NICE is exploring ways of tailoring its approach to appraisals according to the type of product under consideration.

NICE is trying a new 'proportionate' approach to health technology assessments • Source: Shutterstock

By adopting a lighter touch approach for “simpler” treatments and introducing process efficiencies, the UK’s health technology assessment (HTA) institute, NICE, hopes to assess 20% more treatments a year, and in some cases provide faster guidance on whether to recommend products for use on the National Health Service.

NICE aims to achieve this goal from April 2023, by taking a more proportionate approach to how it appraises new treatments, a program that the institute has dubbed PATT (proportionate approach to technology appraisals)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

Recent and Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK Health Data Research Service Looks ‘Encouraging’ For Industry, But Implementation Details Will Be Key

 
• By Anabel Costa-Ferreira

Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.

EU Health Data Space May Speed Up R&D Through Access To Multi-Omics & Clinical Record Data

 
• By Eliza Slawther

The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.